<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03982199</url>
  </required_header>
  <id_info>
    <org_study_id>CR108634</org_study_id>
    <secondary_id>VAC18193RSV2001</secondary_id>
    <nct_id>NCT03982199</nct_id>
  </id_info>
  <brief_title>A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older</brief_title>
  <acronym>CYPRESS</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase 2b Study to Assess the Efficacy, Immunogenicity and Safety of an Ad26.RSV.preF-based Regimen in the Prevention of RT PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Vaccines &amp; Prevention B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Vaccines &amp; Prevention B.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the efficacy of active study vaccine in the&#xD;
      prevention of reverse transcriptase polymerase chain reaction (RT-PCR) confirmed respiratory&#xD;
      syncytial virus (RSV)-mediated lower respiratory tract disease (LRTD), when compared to&#xD;
      placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">May 16, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 3, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Protocol Defined Respiratory Syncytial Virus (RSV)-mediated Lower Respiratory Tract Disease (LRTD) Confirmed by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)</measure>
    <time_frame>Up to 1.6 years</time_frame>
    <description>Percentage of participants with protocol defined RSV-mediated LRTD confirmed by RT-PCR will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with any RT-PCR-confirmed RSV Disease</measure>
    <time_frame>Up to 2.6 years</time_frame>
    <description>Percentage of participants with any RT-PCR-confirmed RSV disease will be reported. RT-PCR-confirmed RSV disease is defined as new onset or worsening of any of the clinical symptoms (lower respiratory tract infection [LRTI], upper respiratory tract infection [URTI]) in combination with RSV confirmation by RT-PCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RSV Neutralization Assay</measure>
    <time_frame>Day 1, Day 15 and Day 365 after vaccination (up to 1.6 years)</time_frame>
    <description>Analysis of neutralizing antibodies to RSV A and/or B strain will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RSV Fusion Protein (F Protein) Binding Antibodies</measure>
    <time_frame>Day 1, Day 15 and Day 365 after vaccination (up to 1.6 years)</time_frame>
    <description>Analysis of antibodies binding to RSV F protein in pre-fusion (pre-F) and/or post-fusion (post-F) form will be performed by enzyme-linked immunosorbent assay (ELISA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interferon Gamma (IFN-gamma) Enzyme-Linked Immunospot (ELISpot) Assay</measure>
    <time_frame>Day 1, Day 15 and Day 365 after vaccination (up to 1.6 years)</time_frame>
    <description>IFN-gamma ELISpot assay will be performed to assess T-cell IFN-gamma responses to RSV F protein peptides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Solicited Local Adverse Events (AEs)</measure>
    <time_frame>7 days after vaccination (Day 8)</time_frame>
    <description>Solicited local AEs includes erythema, swelling, and pain/tenderness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Solicited Systemic AEs</measure>
    <time_frame>7 days after vaccination (Day 8)</time_frame>
    <description>Solicited systemic AEs includes fatigue, headache, nausea, myalgia, and fever (defined as an endogenous elevation of body temperature greater than or equal to [&gt;=]38.0 degree Celsius, as recorded in at least one measurement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Unsolicited AEs</measure>
    <time_frame>28 days after vaccination (Day 29)</time_frame>
    <description>Unsolicited AEs are all AEs for which the participant is specifically not questioned in the participant eDiary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Solicited Local Adverse Events (AEs) in Revaccination Subcohorts</measure>
    <time_frame>7 Days after revaccination at 1 year, 2 years, 3 years and 4 Years (Up to 4.5 Years)</time_frame>
    <description>Solicited local AEs includes erythema, swelling, and pain/tenderness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Solicited Systemic Adverse Events (AEs) in Revaccination Subcohorts</measure>
    <time_frame>7 Days after revaccination at 1 year, 2 years, 3 years and 4 Years (Up to 4.5 Years)</time_frame>
    <description>Solicited systemic AEs includes fatigue, headache, nausea, myalgia, and fever (defined as an endogenous elevation of body temperature &gt;=38.0 degree Celsius, as recorded in at least one measurement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Unsolicited AEs in Revaccination Subcohorts</measure>
    <time_frame>28 Days after revaccination at 1 year, 2 years, 3 years and 4 Years (Up to 4.5 Years)</time_frame>
    <description>Unsolicited AEs are all AEs for which the participant is specifically not questioned in the participant eDiary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Serious Adverse Events (SAEs) During the RSV Season</measure>
    <time_frame>Up to 4.5 years</time_frame>
    <description>An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>6 months after revaccination (up to 4.5 years)</time_frame>
    <description>Percentage of participants with AESIs will be reported. Thrombosis with thrombocytopenia syndrome is considered to be an AESI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With SAEs During the Acute Respiratory Infection (ARI) Follow-up Periods</measure>
    <time_frame>Up to 4.5 years</time_frame>
    <description>An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5815</enrollment>
  <condition>Respiratory Syncytial Viruses</condition>
  <condition>Respiratory Tract Diseases</condition>
  <arm_group>
    <arm_group_label>Group 1: RSV Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single intramuscular (IM) injection of an adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV) vaccine at a single dose level on Day 1. Participants will then be divided into revaccination subcohorts: 1A, 1B, 1C and 1D to receive revaccination with Ad26.RSV.preF based vaccine at 1 year, 2 years, 3 years and 4 years respectively after the first vaccination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single IM injection of placebo control on Day 1. Participants will then be divided into revaccination subcohorts 2A, 2B, 2C, 2D and will first receive Ad26.RSV.preF based vaccine at years 1, 2, 3 and 4. In subcohorts 2A and 2B, participants will receive a revaccination one year later with either Ad26.RSV.preF based vaccine, study vaccine A or study vaccine B.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RSV Vaccine</intervention_name>
    <description>Participants will receive a single IM injection of an Ad26-based RSV vaccine at a single dose level on Day 1 and revaccination after either 1 year, 2 years, 3 years or 4 years.</description>
    <arm_group_label>Group 1: RSV Vaccine</arm_group_label>
    <arm_group_label>Group 2: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive a single IM injection of placebo control on Day 1.</description>
    <arm_group_label>Group 2: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must have a body mass index (BMI) less than (&lt;)40 kilogram per meter&#xD;
             square (kg/m^2)&#xD;
&#xD;
          -  Before randomization, a woman must be: postmenopausal (postmenopausal state is defined&#xD;
             as no menses for 12 months without an alternative medical cause); and not intending to&#xD;
             conceive by any methods&#xD;
&#xD;
          -  Participant must be either in good or stable health. Participants may have mild to&#xD;
             moderate underlying illnesses such as chronic cardiac diseases and chronic lung&#xD;
             disease (asthma and chronic obstructive pulmonary disease [COPD]), congestive heart&#xD;
             failure (CHF), hypertension, type 2 diabetes mellitus, hyperlipoproteinemia, or&#xD;
             hypothyroidism, as long as their symptoms and signs are stable and medically&#xD;
             controlled in the judgment of the investigator. Participants will be included on the&#xD;
             basis of physical examination, medical history, and vital signs performed between&#xD;
             informed consent form (ICF) signature and vaccination on Day 1&#xD;
&#xD;
          -  From the time of vaccination through 3 months after vaccination, participant agrees&#xD;
             not to donate blood&#xD;
&#xD;
          -  Participant must be able to read, understand, and complete questionnaires in the&#xD;
             eDiary (or a paper safety diary, if designated by the sponsor)&#xD;
&#xD;
          -  Participant must be willing to provide verifiable identification, have means to be&#xD;
             contacted and to contact the investigator during the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has an acute illness (including acute respiratory illnesses) or body&#xD;
             temperature greater than or equal to (&gt;=)38.0 degree Celsius (ÂºC) within 24 hours&#xD;
             prior to administration of study vaccine. In such a situation, enrollment at a later&#xD;
             date is permitted&#xD;
&#xD;
          -  Participant has a severe or potentially life-threatening chronic disorder such as&#xD;
             severe chronic cardiac diseases and severe chronic lung disease (asthma and COPD),&#xD;
             advanced CHF, end-stage renal disease with or without dialysis, clinically unstable&#xD;
             cardiac disease, Alzheimer's disease, or has any condition for which, in the opinion&#xD;
             of the investigator, participation would not be in the best interest of the&#xD;
             participant (example: compromise well-being) or that could prevent, limit, or confound&#xD;
             the protocol-specified assessments&#xD;
&#xD;
          -  Participant has a history of malignancy within 5 years before screening (exceptions&#xD;
             are squamous and basal cell carcinomas of the skin and carcinoma in situ of the&#xD;
             cervix, or malignancy, which is considered cured with minimal risk of recurrence)&#xD;
&#xD;
          -  Per medical history, participant has chronic active hepatitis B or hepatitis C&#xD;
             infection&#xD;
&#xD;
          -  Per medical history, participant has human immunodeficiency virus (HIV) type 1 or type&#xD;
             2 infection&#xD;
&#xD;
          -  Participant has a known allergy, or history of anaphylaxis or other serious adverse&#xD;
             reactions to vaccines or vaccine components (including any of the constituents of the&#xD;
             study vaccine)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Vaccines &amp; Prevention B.V. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Vaccines &amp; Prevention B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Phoenix Medical Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paradigm Clinical Research Centers, Inc.</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Institute</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Iowa Clinic</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hutchinson Clinic</name>
      <address>
        <city>Hutchinson</city>
        <state>Kansas</state>
        <zip>67502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc</name>
      <address>
        <city>Richfield</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center For Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundance Clinical Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc</name>
      <address>
        <city>Elkhorn</city>
        <state>Nebraska</state>
        <zip>68022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Medical Associates</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research, Inc.</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester / Rochester General Hospital</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimal Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventavia Research Group, LLC</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research US, Inc</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Chile</country>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 10, 2019</study_first_submitted>
  <study_first_submitted_qc>June 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2019</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical-trials/transparency.&#xD;
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

